The United States has announced a significant commitment to bolster HIV prevention efforts in Zimbabwe, pledging support for access to a new, twice-yearly HIV prevention injection, lenacapavir (LEN), for 271,000 people over the next three years. This initiative, unveiled at the national launch of LEN in Epworth, aims to prevent more than 9,000 new HIV infections within the specified period and concurrently strengthen the country's health system.

Lenacapavir, developed by US-based pharmaceutical company Gilead Sciences, represents a groundbreaking advancement in HIV prevention science. Administered just twice a year, it offers a crucial alternative to daily medication regimens, addressing common barriers such as convenience and privacy. The drug is already in use in the United States, Zambia, and Eswatini, demonstrating its established efficacy and safety.

Speaking at the launch event, US Deputy Chief of Mission Phillip Nervig hailed LEN as a substantial stride forward in prevention. He expressed confidence that with the Zimbabwean government's leadership, an 'AIDS-free generation is within reach.' US Ambassador Pamela Tremont further underscored the drug's importance during her visit to the Epworth Overspill Clinic, one of the initial facilities to offer LEN. She described it as a 'groundbreaking HIV prevention option' that directly tackles challenges associated with daily pill adherence.

Ambassador Tremont emphasized that the US approach has evolved beyond merely providing aid. It now focuses on direct collaboration with recipient countries and communities, like Zimbabwe, to foster self-reliance. This partnership, she noted, is dedicated to combating HIV while simultaneously building a more robust and self-resilient health system for Zimbabwe's future. Washington plans to expand nationwide access to the injection as part of these broader efforts to reinforce the country's health infrastructure.

The introduction of LEN comes at a critical juncture for Zimbabwe, a nation that has achieved commendable progress in reducing HIV infections. Despite these gains, the country continues to face persistent challenges in reaching vulnerable populations and ensuring the sustainability of long-term prevention strategies. The US-supported lenacapavir program is poised to play a pivotal role in overcoming these hurdles and driving Zimbabwe closer to its goal of eradicating HIV.